富硒酵母与TACE治疗原发性肝癌临床疗效及安全性
[摘要] 目的 观察富硒酵母与经肝动脉化疗栓塞术(TACE)治疗原发性肝癌的临床疗效并评价其应用安全性。方法 选择我院2016年11月～2018年5月收治的89例原发性肝癌患者为本次研究对象，按照患者入院后病床单双号分为单号45例为对照组，双号44例为观察组;对照组采用TACE，观察组在对照组的基础上加富硒酵母口服，2个月后对比两组患者疗效及安全性。 结果 血硒含量：治疗前两组比较差异无统计学意义(P>0.05)，观察组治疗后血硒水平明显高于治疗前，与治疗前、对照组治疗后比较，差异有统计学意义(P<0.05);血清VEGF水平：治疗前两组差异无统计学意义(P>0.05)，观察组治疗后明显高于治疗前，差异有统计学意义(P<0.05)，但与对照组治疗后比较相对较低，差异有统计学意义(P<0.05);KPS评分：治疗前两组比较差异无统计学意义(P>0.05)，治疗后观察组下降幅度低于对照组，差异有统计学意义(P<0.05);两组不良反应情况比较，差异无统计学意义(P>0.05)。 结论 富硒酵母联合TACE治疗原发性肝癌能够有效改善患者低硒状态，抑制血清VEGF水平，控制肿瘤进展，且无严重不良反应，安全性高，值得临床推广应用。
[關键词] 富硒酵母;经肝动脉化疗栓塞术;原发性肝癌;安全性
[中图分类号] R735.7 [文献标识码] B [文章编号] 1673-9701(2020)01-0104-04
Clinical efficacy and safety of selenium-enriched yeast and TACE in the treatment of primary liver cancer
CHENG Shufang LIU Weiwen HUI Junguo CHENG Xingyao
Department of Radiology， Lishui Central Hospital in Zhejiang Province， Lishui 323000，China
[Abstract] Objective To observe the clinical efficacy of selenium-enriched yeast and transcatheter arterial chemoembolization(TACE) in the treatment of primary liver cancer and to evaluate its application safety. Methods 89 patients with primary liver cancer admitted to our hospital from November 2016 to May 2018 were selected as the study subjects. According to the patients’ bed number， the patients were divided into two groups， 45 cases in the control group and 44 cases in the observation group. The control group was treated with TACE. The observation group was treated with selenium-enriched yeast orally on the basis of TACE. The efficacy and safety of the two groups were compared after 2 months. Results Selenium content in blood： There was no significant difference between the two groups before treatment(P>0.05). The blood selenium level in the observation group after treatment was significantly higher than that before treatment， and that of the control group both after treatment， the difference was statistically significant(P<0.05). Serum VEGF level： There was no significant difference between the two groups before treatment(P>0.05). The VEGF level in the observation group after treatment was significantly higher than that before treatment， the difference was statistically significant (P<0.05)， and was significantly lower than that of the control group after treatment and the difference was statistically significant(P<0.05). KPS score： There was no significant difference between the two groups before treatment(P>0.05). After treatment， the decrease of the observation group was lower than that of the control group， and the difference was statistically significant(P<0.05). Adverse reactions： There was no significant difference between the control group and the observation group(P>0.05). Conclusion Selenium-enriched yeast combined with TACE in the treatment of primary liver cancer can effectively improve the selenium level in patients， inhibit serum VEGF level， and control tumor progression， with no serious adverse reactions and high safety， which is worthy of clinical application., 百拇医药(程淑芳 刘伟文 惠俊国 程星遥)
[關键词] 富硒酵母;经肝动脉化疗栓塞术;原发性肝癌;安全性
[中图分类号] R735.7 [文献标识码] B [文章编号] 1673-9701(2020)01-0104-04
Clinical efficacy and safety of selenium-enriched yeast and TACE in the treatment of primary liver cancer
CHENG Shufang LIU Weiwen HUI Junguo CHENG Xingyao
Department of Radiology， Lishui Central Hospital in Zhejiang Province， Lishui 323000，China
[Abstract] Objective To observe the clinical efficacy of selenium-enriched yeast and transcatheter arterial chemoembolization(TACE) in the treatment of primary liver cancer and to evaluate its application safety. Methods 89 patients with primary liver cancer admitted to our hospital from November 2016 to May 2018 were selected as the study subjects. According to the patients’ bed number， the patients were divided into two groups， 45 cases in the control group and 44 cases in the observation group. The control group was treated with TACE. The observation group was treated with selenium-enriched yeast orally on the basis of TACE. The efficacy and safety of the two groups were compared after 2 months. Results Selenium content in blood： There was no significant difference between the two groups before treatment(P>0.05). The blood selenium level in the observation group after treatment was significantly higher than that before treatment， and that of the control group both after treatment， the difference was statistically significant(P<0.05). Serum VEGF level： There was no significant difference between the two groups before treatment(P>0.05). The VEGF level in the observation group after treatment was significantly higher than that before treatment， the difference was statistically significant (P<0.05)， and was significantly lower than that of the control group after treatment and the difference was statistically significant(P<0.05). KPS score： There was no significant difference between the two groups before treatment(P>0.05). After treatment， the decrease of the observation group was lower than that of the control group， and the difference was statistically significant(P<0.05). Adverse reactions： There was no significant difference between the control group and the observation group(P>0.05). Conclusion Selenium-enriched yeast combined with TACE in the treatment of primary liver cancer can effectively improve the selenium level in patients， inhibit serum VEGF level， and control tumor progression， with no serious adverse reactions and high safety， which is worthy of clinical application., 百拇医药(程淑芳 刘伟文 惠俊国 程星遥)